The safety of IMLYGIC® (talimogene laherparepvec) was evaluated in 419 patients who received at least 1 dose of either IMLYGIC® (n = 292) or subcutaneously administered granulocyte-macrophage colony-stimulating factor (GM-CSF) (n = 127) in a phase 3, multicenter, open-label, randomized clinical study of patients with stage IIIB, IIIC, and IV melanoma that was not considered to be surgically resectable. The median duration of exposure to IMLYGIC® was 23 weeks (5.3 months). Twenty-six patients were exposed to IMLYGIC® for at least 1 year.1,2
Most adverse reactions reported were mild or moderate in severity and generally resolved within 72 hours. The most common grade 3 or higher adverse reaction was cellulitis.1
Pyrexia, chills, and influenza-like illness can occur any time during IMLYGIC® treatment but were more frequent during the first 3 months of treatment.1
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Help for locating centers and clinics that may provide IMLYGIC® (talimogene laherparepvec) treatment to appropriate patients.
GET STARTED >
See the next section for key information about IMLYGIC® administration.
DOSING & ADMINISTRATION >